Developing NICE guidelines: the manual appendix H

Process and methods guides
Appendix H Appraisal checklists, evidence tables, GRADE and economic profiles

This aims to give examples of checklists that can be used to assess risk of bias or quality of studies when developing guidelines. The decision about which checklist to be used should be made as part of the review protocol development. The checklist should allow assessment of those features considered important – these may be study design specific or specific to the topic. As such, additional items may need to be included, or minor modification made. Where this is the case, this should be documented, and where significant, agreed with members of NICE staff with responsibility for quality assurance.

Examples of checklists for study types used in service delivery guidance can be found in the interim guide for service delivery guidance.
Algorithm for classifying quantitative (experimental and observational) study designs

The algorithm below can be used to classify quantitative study designs and guide decisions about which checklist should be used.

[Diagram of the algorithm]

1. Does the study compare outcomes between 2 groups (e.g., intervention/exposure vs. comparison)?
   - No: Non-comparative study (case series, case study, exploratory research, focus groups, etc.)
   - Yes: Did investigator assign intervention or exposure?

2. Did investigator assign intervention or exposure?
   - Yes: Experimental study
   - No: Observational study

3. Before and after study or interrupted time series?
   - No: Concurrent control group included in study?
     - Yes: Interventions/controls randomly allocated?
       - Yes: Randomised controlled trial
       - No: Non-randomised controlled trial
     - No: Case control study
   - Yes: Concurrent control group included in study?
     - Yes: Representative (random) samples of the population?
       - Yes: Exposure and outcome assessed at the same point in time?
         - Yes: Sample group is population level or individual level?
           - Yes: Prospective cohort study
           - No: Retrospective cohort study
         - No: Groups followed forward in time?
           - Yes: Cross sectional study
           - No: Individual

4. Individuals or groups (clusters) randomised?
   - Yes: Cluster randomised controlled trial
   - No: Individual randomised controlled trial

5. Population or individual?
   - Yes: Correlation study
   - No: Population
Appraisal checklists: systematic reviews and meta-analyses
ROBIS – currently in development

Amstar www.amstar.ca

DSU NMA methodology checklist

CASP systematic review checklist www.casp-uk.net/#!casp-tools-checklists/c18f8

Appraisal checklists: randomised controlled trials (individual or cluster)
Cochrane RoB tool

Effective Practice and Organisation of Care (EPOC) RoB Tool
epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk
%20of%20bias%20criteria%20for%20EPOC%20reviews.doc

CASP RCT checklist www.casp-uk.net/#!casp-tools-checklists/c18f8

Appraisal checklists: quantitative intervention studies (including non-randomised controlled trials, before and after studies, interrupted time series)
GATE - Effective Public Health Practice Project Quality assessment tool for quantitative studies

Effective Practice and Organisation of Care (EPOC) RoB Tool (for studies with a control group)
epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk
%20of%20bias%20criteria%20for%20EPOC%20reviews.doc

Effective Practice and Organisation of Care (EPOC) RoB Tool (for ITS)
epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk
%20of%20bias%20criteria%20for%20EPOC%20reviews.doc

Appraisal checklists: correlation studies
Cochrane RoB tool for non-randomised studies

Effective Practice and Organisation of Care (EPOC) RoB Tool (for studies with a control group)
epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.doc

Newcastle-Ottowa scale  www.ohri.ca/programs/clinical_epidemiology/oxford.asp

Downs & Black checklist for measuring quality  
http://jech.bmj.com/content/52/6/377.abstract

Quality assessment for quantitative studies  www.ephpp.ca/tools.html

Effective Practice and Organisation of Care (EPOC) RoB Tool (for ITS)  
epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.doc

**Appraisal checklists: cohort studies (prospective and retrospective) and cross-sectional studies**

Cochrane RoB tool for non-randomised studies

Effective Practice and Organisation of Care (EPOC) RoB Tool (for studies with a control group)  
epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.doc

Newcastle-Ottowa scale  www.ohri.ca/programs/clinical_epidemiology/oxford.asp

Downs & Black checklist for measuring quality  
http://jech.bmj.com/content/52/6/377.abstract

Quality assessment for quantitative studies  www.ephpp.ca/tools.html

GRACE  www.graceprinciples.org

CASP cohort checklist  www.casp-uk.net/#!casp-tools-checklists/c18f8

Effective Practice and Organisation of Care (EPOC) RoB Tool (for ITS)  
epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.doc
**Appraisal checklists: case–control studies**

Cochrane RoB tool for non-randomised studies

Effective Practice and Organisation of Care (EPOC) RoB Tool (for studies with a control group)

[epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.doc](epocoslo.cochrane.org/sites/epocoslo.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.doc)

Newcastle-Ottowa scale [www.ohri.ca/programs/clinical_epidemiology/oxford.asp](www.ohri.ca/programs/clinical_epidemiology/oxford.asp)

Downs& Black checklist for measuring quality

[http://jech.bmj.com/content/52/6/377.abstract](http://jech.bmj.com/content/52/6/377.abstract)

CASP case-control checklist [www.casp-uk.net/#!casp-tools-checklists/c18f8](www.casp-uk.net/#!casp-tools-checklists/c18f8)

**Appraisal checklists: economic evaluations**

This checklist can be used to determine whether an economic evaluation provides evidence that is useful to inform the decision-making of the Committee (see chapter 7). It judges the applicability of the study and the limitations.

The robustness of the study results to methodological limitations may sometimes be apparent from reported sensitivity analyses. If not, judgement will be needed to assess whether a limitation would be likely to change the results and conclusions. The judgements should be recorded and presented in the guideline. The ‘comments’ column in the checklist should be used to record reasons for these judgements, as well as additional details about the studies where necessary.

If this checklist is not considered appropriate, other economic evaluation checklists, such as [CHEERS](http://jech.bmj.com/content/52/6/377.abstract), can be used.

If necessary, the health technology assessment checklist for decision-analytic models (Philips et al. 2004) may also be used to give a more detailed assessment of the methodological quality of modelling studies.
## Checklist: economic evaluations

### Study identification
Include author, title, reference, year of publication

<table>
<thead>
<tr>
<th>Guidance topic:</th>
<th>Question no:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Checklist completed by:</td>
<td></td>
</tr>
</tbody>
</table>

### Section 1: Applicability (relevance to specific review questions and the NICE reference case as described in section 7.5)
This checklist should be used first to filter out irrelevant studies.

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes/partly/no/unclear/NA</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Is the study population appropriate for the review question?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 Are the interventions appropriate for the review question?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.3 Is the system in which the study was conducted sufficiently similar to the current UK context?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.4 Are the perspectives clearly stated and are they appropriate for the review question?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 Are all direct effects on individuals included, and are all other effects included where they are material?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.6 Are all future costs and outcomes discounted appropriately?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.7 Is QALY used as an outcome, and was it derived using NICE’s preferred methods? If not, describe rationale and outcomes used in line with analytical perspectives taken (item 1.4 above).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.8 Are costs and outcomes from other sectors fully and appropriately measured and valued?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.9 Overall judgement:</td>
<td>Directly applicable/partially applicable/not applicable</td>
<td></td>
</tr>
</tbody>
</table>

There is no need to use section 2 of the checklist if the study is considered ‘not applicable’.

### Other comments:

<table>
<thead>
<tr>
<th>Section 2: Study limitations (the level of methodological quality)</th>
<th>Yes/partly/no/unclear/NA</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>This checklist should be used once it has been decided that the study is sufficiently applicable to the context of the guideline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Does the model structure adequately reflect the nature of the topic under evaluation?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2</td>
<td>Is the time horizon sufficiently long to reflect all important differences in costs and outcomes?</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>2.3</td>
<td>Are all important and relevant outcomes included?</td>
<td></td>
</tr>
<tr>
<td>2.4</td>
<td>Are the estimates of baseline outcomes from the best available source?</td>
<td></td>
</tr>
<tr>
<td>2.5</td>
<td>Are the estimates of relative intervention effects from the best available source?</td>
<td></td>
</tr>
<tr>
<td>2.6</td>
<td>Are all important and relevant costs included?</td>
<td></td>
</tr>
<tr>
<td>2.7</td>
<td>Are the estimates of resource use from the best available source?</td>
<td></td>
</tr>
<tr>
<td>2.8</td>
<td>Are the unit costs of resources from the best available source?</td>
<td></td>
</tr>
<tr>
<td>2.9</td>
<td>Is an appropriate incremental analysis presented or can it be calculated from the data?</td>
<td></td>
</tr>
<tr>
<td>2.10</td>
<td>Are all important parameters whose values are uncertain subjected to appropriate sensitivity analysis?</td>
<td></td>
</tr>
<tr>
<td>2.11</td>
<td>Is there any potential conflict of interest?</td>
<td></td>
</tr>
<tr>
<td>2.12</td>
<td><strong>Overall assessment:</strong> Minor limitations/potentially serious limitations/very serious limitations</td>
<td></td>
</tr>
</tbody>
</table>

**Other comments:**

If the economic evaluation is a cost-benefit analysis, the following questions should also be addressed:

1. Are money-costs and ‘benefits’ which are savings of future money-costs evaluated?

2. Have all important and relevant costs and outcomes for each alternative been quantified in money terms?

   If not, state which items were not quantified, and the likely extent of their importance in terms of influencing the benefit/cost ratio.

3. Has at least 1 of net present value, benefit/cost ratio and payback period been estimated?
4. Were any assumptions of materiality made? That is, were any items where costs and/or benefits were sufficiently small that their addition to the analysis would not have changed any recommendations in the guidelines?

If the economic evaluation is a cost-consequences analysis, the following questions should also be addressed:

1. Have all important and relevant costs and outcomes for each alternative been quantified, where appropriate? If not, state which items were not quantified. Were they still used in the CCA and how were they used?

2. Were any assumptions of materiality made to restrict the number of consequences considered? That is, were any items where costs and/or benefits were sufficiently small that their addition to the analysis would not have changed any recommendations in the guidelines?

3. Was any analysis of correlation between consequences carried out to help control for double counting?

4. Was there any indication of the relative importance of the different consequences by a suggested weighting of them?

5. Were there any theoretical relationships between consequences that could have been taken into account in determining weights?

6. Were the consequences considered one by one to see if a decision could be made based on a single consequence or a combination of a small number of consequences?

7. Were the consequences considered in subgroups of all the consequences in the analysis to see if a decision could be made based on a particular subgroup?

8. Was an MCDA (multiple criteria decision analysis) or other published method of aggregation of consequences attempted?
Notes on use of the checklist: economic evaluations

For all questions:

- answer ‘yes’ if the study fully meets the criterion
- answer ‘partly’ if the study largely meets the criterion but differs in some important respect
- answer ‘no’ if the study deviates substantively from the criterion
- answer ‘unclear’ if the report provides insufficient information to judge whether the study complies with the criterion
- answer ‘NA (not applicable)’ if the criterion is not relevant in a particular instance.

For ‘partly’ or ‘no’ responses, use the comments column to explain how the study deviates from the criterion.

Section 1: Applicability

1.1 Is the study population appropriate for the review question?

The study population should be defined as precisely as possible and should be in line with that specified in the guidance scope and any related review protocols.

This includes consideration of appropriate subgroups that require special attention. For many interventions, the capacity to benefit will differ for participants with differing characteristics. This should be explored separately for each relevant subgroup as part of the base-case analysis by the provision of estimates of effectiveness and cost effectiveness. The characteristics of participants or communities in each subgroup should be clearly defined and, ideally, should be identified on the basis of an a priori expectation of differential effectiveness or cost effectiveness as a result of biologically, sociologically or economically plausible known mechanisms, social characteristics or other clearly justified factors.

Answer ‘yes’ if the study population is fully in line with that in the review questions and if the study differentiates appropriately between important subgroups. Answer ‘partly’ if the study population is similar to that in the review questions but: (i) it differs in some important respects; or (ii) the study fails to differentiate between important
subgroups. Answer ‘no’ if the study population is substantively different from that in the review questions.

1.2 Are the interventions/services/programmes appropriate for the review question?
All relevant alternatives should be included, as specified in the guidance scope and any related review protocols. These should include routine and best practice in UK settings, existing NICE guidance and other feasible options.

Answer ‘yes’ if the analysis includes all options considered relevant for the review question, even if it also includes other options that are not relevant. Answer ‘partly’ if the analysis omits 1 or more relevant options but still contains comparisons likely to be useful for the guidance. Answer ‘no’ if the analysis does not contain any relevant comparisons.

1.3 Is the system in which the study was conducted sufficiently similar to the current UK context?
This relates to the overall structure of the system within which the interventions were delivered. For example, an intervention might be delivered on a residential basis in one country whereas in the UK it would be provided in the community. This might significantly influence the use of resources and costs, thus limiting the applicability of the results to a UK setting. In addition, old UK studies may be severely limited in terms of their relevance to current practice.

Answer ‘yes’ if the study was conducted within the UK and is sufficiently recent to reflect current practice. For non-UK or older UK studies, answer ‘partly’ if differences in the setting are unlikely to substantively change the cost-effectiveness estimates. Answer ‘no’ if the setting is so different that the results are unlikely to be applicable in the current UK context.

1.4 Are the perspectives clearly stated, and what are they?
The decision-making perspective of an economic evaluation determines the range of costs that should be included in the analysis. Answer ‘yes’ if the study clearly and correctly states the perspective used, and whether that perspective is appropriate. Answer ‘partly’ if the perspective stated is not the perspective used. Answer ‘no’ if the study does not state the perspective or that the perspective is not appropriate.
1.5 Are all direct effects on individuals included, and are all other effects included where they are material?

For an NHS and personal social services (PSS) perspective, outcomes should include all direct effects, whether for individuals directly affected or, when relevant, other people (often other family members or carers). This is consistent with an objective of maximising benefits from available public sector resources.

Answer 'yes' if the analysis excludes non-related effects (or if such effects can be excluded from the results). Answer 'partly' if the analysis includes some non-related effects but these are small and unlikely to change the cost-effectiveness results. Answer 'no' if the analysis includes significant non-related effects that are likely to change the cost-effectiveness results.

1.6 Are all future costs and outcomes discounted appropriately?

The need to discount to a present value is widely accepted in economic evaluation, although the specific rate is variable across jurisdictions and over time. NICE considers that it is usually appropriate to discount costs and effects at the same rate. The annual rate of 3.5%, based on the recommendations of the UK Treasury for the discounting of costs, should be applied to both costs and effects. Sensitivity analyses using rates of 1.5% for both costs and effects may be presented alongside the reference-case analysis.

Answer 'yes' if both costs and effects are discounted at 3.5% per year (or at another rate considered appropriate). Answer 'partly' if costs and effects are discounted at a rate similar to the rate considered appropriate (for example, costs and effects are both discounted at 3% per year where the appropriate rate is 3.5%). Answer 'no' if costs and/or effects are not discounted, or if they are discounted at a rate (or rates) different from the rate considered appropriate (for example, 5% for both costs and effects, or 6% for costs and 1.5% for effects where the appropriate rate is 3.5%). Note in the comments column what discount rates have been used. If all costs and effects accrue within a short time (roughly a year), answer 'NA'.

1.7 How is the value of effects expressed?

The QALY is a measure of a person’s length of life weighted by a valuation of their health-related quality of life (HRQoL) over that period. For review questions where
the QALY is not be the most appropriate measure of effects, other measures based on social care-related quality of life or capability may be used.

Answer ‘yes’ if the effectiveness of the intervention is measured using QALYs or an appropriate social care-related equivalent; answer ‘no’ if not. Use the comments column to describe the measure of effects used. There may be circumstances when such measures cannot be obtained or where the underlying assumptions are considered inappropriate. In such situations answer ‘no’, but consider retaining the study for appraisal. Similarly, answer ‘no’ but retain the study for appraisal if it does not include appropriate measures of effects but is still thought to be useful for Committee decision-making: for example, if the evidence indicates that an intervention might be dominant, and estimates of the relative costs of the interventions from a cost-minimisation study are likely to be useful. When economic evaluations not using appropriate measures of effects are retained for full critical appraisal, use the comments column to note why.

1.8 Are costs and outcomes from other sectors fully and appropriately measured and valued?

Studies can include costs accruing to other sectors of the economy or benefits gained by these sectors. Not all of these benefits can be translated into measures of effects (for example, the ability to return to work earlier). Answer ‘yes’ if all the costs and all the benefits have been included, if they are appropriately measured and if they are appropriately valued. Answer ‘partly’ if omissions are not material and answer ‘no’ if some major cost or benefit is omitted, is improperly measured or improperly valued. Use the comments column to describe costs and outcomes relating to other sectors.

1.9 Overall judgement

Classify the applicability of the economic evaluation to the guideline, the current UK situation and the context for NICE guidance as 1 of the following:

- **Directly applicable** – the study meets all applicability criteria, or fails to meet 1 or more applicability criteria but this is unlikely to change the conclusions about cost effectiveness.
- **Partially applicable** – the study fails to meet 1 or more of the applicability criteria, and this could change the conclusions about cost effectiveness.
• **Not applicable** – the study fails to meet 1 or more of the applicability criteria, and this is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from further consideration and there is no need to continue with the rest of the checklist.

**Section 2: Study limitations**

2.1 Does the model structure adequately reflect the nature of the topic under evaluation?

This relates to the choice of model and its structural elements (including cycle length in discrete time models, if appropriate). Model type and its structural aspects should be consistent with a coherent theory of the needs under evaluation. The selection of care pathways, whether individual states or branches in a decision tree, should be based on the underlying biological, sociological or economic processes of the topic under study and the potential impact (benefits and adverse consequences) of the interventions of interest.

Answer ‘yes’ if the model design and assumptions appropriately reflect the condition and interventions of interest. Answer ‘partly’ if there are aspects of the model design or assumptions that do not fully reflect the condition or interventions but these are unlikely to change the cost-effectiveness results. Answer ‘no’ if the model omits some important aspect of the condition or intervention and this is likely to change the cost-effectiveness results. Answer ‘NA’ for economic evaluations based on data from a study which do not extrapolate intervention outcomes or costs beyond the study context or follow-up period.

2.2 Is the time horizon sufficiently long to reflect all important differences in costs and outcomes?

The time horizon is the period of analysis of the study: the length of follow-up for participants in a trial-based evaluation, or the period of time over which the costs and outcomes for a cohort are tracked in a modelling study. This time horizon should always be the same for costs and outcomes, and should be long enough to include all relevant costs and outcomes relating to the intervention. A time horizon shorter than lifetime could be justified if there is no differential mortality effect between options, and the differences in costs, social care-related quality of life or other relevant outcomes relate to a relatively short period.
Answer ‘yes’ if the time horizon is sufficient to include all relevant costs and outcomes. Answer ‘partly’ if the time horizon may omit some relevant costs and outcomes but these are unlikely to change the cost-effectiveness results. Answer ‘no’ if the time horizon omits important costs and outcomes and this is likely to change the cost-effectiveness results.

2.3 Are all important and relevant outcomes included?

All relevant outcomes should include direct effects relating to harms from the intervention as well as any potential benefits.

Answer ‘yes’ if the analysis includes all relevant and important harms and benefits. Answer ‘partly’ if the analysis omits some harms or benefits but these would be unlikely to change the cost-effectiveness results. Answer ‘no’ if the analysis omits important harms and/or benefits that would be likely to change the cost-effectiveness results.

2.4 Are the estimates of baseline outcomes from the best available source?

The sources and methods for eliciting baseline probabilities should be described clearly. These data can be based on ‘natural history’ (outcomes in the absence of intervention), sourced from cohort studies. Baseline probabilities may also be derived from the control arms of experimental studies. Sometimes it may be necessary to rely on expert opinion for particular parameters.

Answer ‘yes’ if the estimates of baseline outcomes reflect the best available evidence as identified from a recent well-conducted systematic review of the literature. Answer ‘partly’ if the estimates are not derived from a systematic review but are likely to reflect outcomes for the relevant group of people in England (for example, if they are derived from a large UK-relevant cohort study). Answer ‘no’ if the estimates are unlikely to reflect outcomes for the relevant group of people in England.

2.5 Are the estimates of relative intervention effects from the best available source?

Evidence on outcomes should be obtained from a systematic review with meta-analysis where appropriate.
The methods and assumptions that are used to extrapolate short-term results to final outcomes should be clearly presented.

Answer ‘yes’ if the estimates of the effect of intervention appropriately reflect all relevant studies of the best available quality, as identified through a recent well-conducted systematic review of the literature. Answer ‘partly’ if the estimates of the effect of intervention are not derived from a systematic review but are similar in magnitude to the best available estimates (for example, if the economic evaluation is based on a single large study with effects similar to pooled estimates from all relevant studies). Answer ‘no’ if the estimates of the effect of intervention are likely to differ substantively from the best available estimates.

2.6 Are all important and relevant costs included?

Costs related to the topic of interest and incurred in additional years of life gained as a result of intervention should be included in the base-case analysis. Costs that are considered to be unrelated to the topic or intervention of interest should be excluded. If introduction of the intervention requires additional infrastructure to be put in place, consideration should be given to including such costs in the analysis.

Answer ‘yes’ if all important and relevant resource use and costs are included given the perspective and the research question in the economic study under consideration. Answer ‘partly’ if some relevant resource items are omitted but these are unlikely to affect the cost-effectiveness results. Answer ‘no’ if important resource items are omitted and these are likely to affect the cost-effectiveness results.

2.7 Are the estimates of resource use from the best available source?

It is important to quantify the effect of the interventions on resource use in terms of physical units (for example, days in care or contacts with practitioners) and valuing those effects in monetary terms using appropriate prices and unit costs. Evidence on resource use should be identified systematically. When expert opinion is used as a source of information, any formal methods used to elicit these data should be clearly reported.

Answer ‘yes’ if the estimates of resource use appropriately reflect all relevant evidence sources of the best available quality, as identified through a recent well-
conducted systematic review of the literature. Answer ‘partly’ if the estimates of resource use are not derived from a systematic review but are similar in magnitude to the best available estimates. Answer ‘no’ if the estimates of resource use are likely to differ substantively from the best available estimates.

2.8 Are the unit costs of resources from the best available source?

Resources should be valued using the prices relevant to the agencies that deliver the interventions. A first point of reference in identifying costs and prices should be any current official listing published by relevant government departments.

When the acquisition price paid for a resource differs from the public list price, the public list price should be used in the base-case analysis. Sensitivity analysis should assess the implications of variations from this price. When cost data are taken from the literature, the methods used to identify the sources should be defined. When several alternative sources are available, a justification for the costs chosen should be provided and discrepancies between the sources explained. When appropriate, sensitivity analysis should have been undertaken to assess the implications for results of using alternative data sources.

Answer ‘yes’ if resources are valued using up-to-date prices relevant to the appropriate sectors. Answer ‘partly’ if the valuations of some resource items differ from current relevant unit costs but this is unlikely to change the cost-effectiveness results. Answer ‘no’ if the valuations of some resource items differ substantively from current relevant unit costs and this is likely to change the cost-effectiveness results.

2.9 Is an appropriate incremental analysis presented or can it be calculated from the data?

An appropriate incremental analysis is one that compares the expected costs and outcomes of one intervention with the expected costs and outcomes of the next-best non-dominated alternative.

Standard decision rules should be followed when combining costs and effects, and should reflect any situation where there is dominance or extended dominance. When there is a trade-off between costs and effects, the results should be presented as an incremental cost-effectiveness ratio (ICER): the ratio of the difference in mean costs to the difference in mean outcomes of a technology compared with the next best
alternative. Where benefits are expressed as QALYs, in addition to ICERs, expected net monetary or health benefits can be presented using values placed on a QALY gained of £20,000 and £30,000. However, it may not be possible to place such values on other measures of benefits that are used in social care economic evaluation.

For cost-consequences analyses, appropriate incremental analysis can only be done by selecting one of the consequences as the primary measure of effectiveness, providing the consequences are independent of one another.

Answer ‘yes’ if appropriate incremental results are presented, or if data are presented that allow the reader to calculate the incremental results. Answer ‘no’ if: (i) simple ratios of costs to effects are presented for each alternative compared with a standard intervention; or (ii) if options subject to simple or extended dominance are not excluded from the incremental analyses.

2.10 Are all important parameters whose values are uncertain subjected to appropriate sensitivity analysis?

There are a number of potential selection biases and uncertainties in any evaluation (trial- or model-based) and these should be identified and quantified where possible. There are 3 types of bias or uncertainty to consider:

- Structural uncertainty – for example in relation to the categorisation of different states of capability/wellbeing/health and the representation of different pathways of care. These structural assumptions should be clearly documented and the evidence and rationale to support them provided. The impact of structural uncertainty on estimates of cost effectiveness should be explored by separate analyses of a representative range of plausible scenarios.

- Source of values to inform parameter estimates – the implications of different estimates of key parameters (such as estimates of relative effectiveness) must be reflected in sensitivity analyses (for example, through the inclusion of alternative scenarios). Inputs must be fully justified, and uncertainty explored by sensitivity analysis using alternative input values.

- Parameter precision – uncertainty around the mean capability/wellbeing/health and cost inputs in the model. Distributions should be assigned to characterise the
uncertainty associated with the (precision of) mean parameter values. Probabilistic sensitivity analysis is preferred, as this enables the uncertainty associated with parameters to be simultaneously reflected in the results of the model. In non-linear decision models – when there is not a straight-line relationship between inputs and outputs of a model (such as Markov models) – probabilistic methods provide the best estimates of mean costs and outcomes. Simple decision trees are usually linear. The mean value, distribution around the mean, and the source and rationale for the supporting evidence should be clearly described for each parameter included in the model. Evidence about the extent of correlation between individual parameters should be considered carefully and reflected in the probabilistic analysis. Assumptions made about the correlations should be clearly presented.

Answer ‘yes’ if an extensive sensitivity analysis was undertaken that explored all key uncertainties in the economic evaluation. Answer ‘partly’ if the sensitivity analysis failed to explore some important uncertainties in the economic evaluation. Answer ‘no’ if the sensitivity analysis was very limited and omitted consideration of a number of important uncertainties, or if the range of values or distributions around parameters considered in the sensitivity analysis were not reported.

2.11 Is there any potential conflict of interest?

The British Medical Journal (BMJ) defines competing interests for its authors as follows: ‘A competing interest exists when professional judgment concerning a primary interest (such as patients’ welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors of a BMJ article when they have a financial interest that may influence, probably without their knowing, their interpretation of their results or those of others.’

Whenever a potential financial conflict of interest is possible, this should be declared.

Answer ‘yes’ if the authors declare that they have no financial conflicts of interest. Answer ‘no’ if clear financial conflicts of interest are declared or apparent (for example, from the stated affiliation of the authors). Answer ‘unclear’ if the article does not indicate whether or not there are financial conflicts of interest.
2.12 Overall assessment

The overall methodological study quality of the economic evaluation should be classified as 1 of the following:

- **Minor limitations** – the study meets all quality criteria, or fails to meet 1 or more quality criteria but this is unlikely to change the conclusions about cost effectiveness.

- **Potentially serious limitations** – the study fails to meet 1 or more quality criteria, and this could change the conclusions about cost effectiveness.

- **Very serious limitations** – the study fails to meet 1 or more quality criteria, and this is highly likely to change the conclusions about cost effectiveness. Such studies should usually be excluded from further consideration.

**Supporting references**


**Appraisal checklists: qualitative studies**

CERQual – in development


National Training and Research Appraisal Group (NTRAG); contact: info@ntrag.co.uk

**British Sociological Association (BSA)**


CASP qualitative checklist [www.casp-uk.net/#!casp-tools-checklists/c18f8](http://www.casp-uk.net/#!casp-tools-checklists/c18f8)

**Appraisal checklists: diagnostic test accuracy**

QUADAS 2 [QUADAS website](http://quadas.org/).

CASP diagnostic test accuracy checklist [www.casp-uk.net/#!casp-tools-checklists/c18f8](http://www.casp-uk.net/#!casp-tools-checklists/c18f8)

**Appraisal checklists: prognostic studies**

PROBAS – in development


CASP clinical prediction rule checklist [www.casp-uk.net/#!casp-tools-checklists/c18f8](http://www.casp-uk.net/#!casp-tools-checklists/c18f8)
**Appraisal checklists: generic**

There may be some reviews where it is not helpful to use different checklists for the different study designs (for example, in a complex mixed methods review). In such cases, a single checklist that can be applied to different study designs may be used.


**Examples of evidence tables**

This section includes examples of evidence tables for those study designs that are expected to be used in the evidence reviews for NICE guidelines.

Below are examples of the type of information and data NICE requires in table format in evidence reviews. It is not possible to provide a fixed template for all evidence tables that will suit all topics. The range, type, quantity and quality of evidence identified will inevitably vary and these tables are presented as examples only of how information and data should be presented.

If additional analysis or additional calculation (e.g. calculating numbers needed to treat, odds ratios, risk ratios) of data is required and feasible, these must be clearly noted as ‘calculated by the review team’.
### Example of an evidence table for reviews

**Title:** (review question)

<table>
<thead>
<tr>
<th>Bibliographic reference</th>
<th>Review design</th>
<th>Study quality</th>
<th>Review search parameters</th>
<th>Review population and setting</th>
<th>Intervention(s)</th>
<th>Outcomes and methods of analysis</th>
<th>Results</th>
<th>Limitations</th>
<th>Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sources Methods of searching Dates Inc/exc criteria Number of studies</td>
<td>Details (demographics) Missing information</td>
<td>Intervention in detail (who, where, when) Controls/comparator also in detail</td>
<td>Objective/subjective Time points Health inequalities impact</td>
<td>Identified by authors Identified by developers</td>
<td>Source of funding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The detailed information under each heading should be agreed at the review protocol stage and be consistently completed across the review. The italicised text above is provided as an example of the types of information that could be included. The required information is specified below.


[2] Review type: for example, systematic review with meta-analysis.

[3] Number of studies: total number of studies included in the review.

[4] Study characteristics: characteristics relevant to the area of interest: study design, other restrictions.

[5] Intervention: treatment, service, procedure or test studied. If important for the study, specify duration of treatment.

[6] Setting: the settings where the interventions was delivered (for example care homes).


[8] Outcome measures: list all outcome measures defined in the review protocol, including associated harms.
[9] Results: for example, summary effect size from a meta-analysis.

[10] Source of funding: for example the Department of Health or Economic and Social Research Council. Also detail the role of funding organisations.

[11] Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of the review (++, +, - if used) or for use in GRADE assessment

[12] Additional comments: additional characteristics and/or interpretations of the review that the reviewer wishes to record. These might include important flaws and limitations in the review not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the review
Example of an evidence table for intervention studies

Title: (review question)

<table>
<thead>
<tr>
<th>Bibliographic reference</th>
<th>Study type</th>
<th>Study quality</th>
<th>Intervention (who, where, when)</th>
<th>Comparator Methods to minimize confounders</th>
<th>Setting Country/Location</th>
<th>Power Information Method of recruitment</th>
<th>Intervention characteristics Information on representativeness</th>
<th>Number of participants</th>
<th>Length of follow-up</th>
<th>Methods of analysis</th>
<th>Results</th>
<th>Limitations</th>
<th>Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The detailed information under each heading should be agreed at the review protocol stage and be consistently completed across the review. The italicised text above is provided as an example of the types of information that could be included. The required information is specified below.


[2] Study type: for example, randomised controlled trial, cohort or case-control studies.

[3] Number of participants: total number of participants included in the study, including number of participants in each arm, with inclusion and exclusion criteria. Also record the numbers of participants who started and completed the study.

[4] Participant characteristics: characteristics relevant to the area of interest: age, sex, ethnic origin, condition status and comorbidity.

[5] Intervention: treatment, service, procedure or test studied. If important for the study, specify duration of treatment.

[6] Setting: the settings where the interventions was delivered (for example care homes).


[8] Length of follow-up: the length of time that participants take part in the study for, from first staging treatment until either a pre-specified end-point or the end of the data-gathering phase is reached. If the study is stopped earlier than originally planned for any reason, this should be noted here.

[9] Outcome measures: list all outcome measures defined in the review protocol, including associated harms.

[10] Effect size: for example, raw data from the study that allow further analyses, as required. Give confidence intervals whenever possible.
[11] Source of funding: for example the Department of Health or Economic and Social Research Council. Also detail the role of funding organisations.

[12] Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (++, +, - if used) or for use in GRADE assessment

[13] Additional comments: additional characteristics and/or interpretations of the studies that the reviewer wishes to record. These might include important flaws and limitations in the study not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the study
Example of an evidence table for studies of diagnostic test accuracy
Title: (review question)

<table>
<thead>
<tr>
<th>Bibliographic reference</th>
<th>Study type</th>
<th>Study quality</th>
<th>Type of test</th>
<th>Reference standard</th>
<th>Number of participants</th>
<th>Prevalence</th>
<th>Participant characteristics</th>
<th>Sensitivity and specificity or raw data for 2x2 table</th>
<th>Positive and negative predictive values</th>
<th>Additional comments</th>
</tr>
</thead>
</table>

The detailed information under each heading should be agreed at the review protocol stage and be consistently completed across the review. The italicised text above is provided as an example of the types of information that could be included. The required information is specified below.


[2] Study type: for example, cross-sectional, cohort or case–control studies.


[4] Number of participants: total number of patients included in the study, with inclusion and exclusion criteria.


[6] Participant characteristics: characteristics relevant to the area of interest: age, sex, ethnic origin, comorbidity, disease status, community- or hospital-based.

[7] Type of test: description of the diagnostic test used in the study. Specify the test threshold where applicable.

[8] Reference standard: used as a measure of outcome. Specify if it is a ‘gold standard’ or ‘current best practice’.

[9] Sensitivity: proportion of individuals classified as positive by the gold (or reference) standard who are correctly identified by the study test. Specificity: proportion of individuals classified as negative by the gold (or reference) standard who are correctly identified by the study test.
Raw data for 2x2 table: study data collected from tests to calculate sensitivity, specificity, and positive and negative predictive values (see example table below)

<table>
<thead>
<tr>
<th>Test</th>
<th>Disease or outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Present</td>
</tr>
<tr>
<td>+</td>
<td>a (true positive)</td>
</tr>
<tr>
<td>−</td>
<td>c (false negative)</td>
</tr>
</tbody>
</table>

[10] Positive predictive value: proportion of individuals with a positive test result who actually have the disease.
Negative predictive value: proportion of individuals with a negative test result who do not have the disease.

[11] Source of funding: government funding (for example, NHS), voluntary/charity (for example, Wellcome Trust), pharmaceutical company; and the role of funding organisations.

[12] Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (++, +, - if used) or for use in GRADE assessment

[13] Additional comments: Additional characteristics and/or interpretations of the studies that the reviewer wishes to record. These might include important flaws in the study not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the study (for example, if a test is one of a sequence of tests; if its utility was determined).
Example of an evidence table for prognostic studies

Title: (review question)

<table>
<thead>
<tr>
<th>Bibliographic reference</th>
<th>Study type</th>
<th>Study quality</th>
<th>Prognostic factor(s)</th>
<th>Number of participants</th>
<th>Participant characteristics</th>
<th>Length of follow-up</th>
<th>Outcome measures</th>
<th>Results</th>
<th>Additional comments</th>
</tr>
</thead>
</table>

The detailed information under each heading should be agreed at the review protocol stage and be consistently completed across the review. The italicised text above is provided as an example of the types of information that could be included. The required information is specified below.


[2] Study type: for example, cohort, nested cohort, case series.


[4] Number of participants: total number of patients included in the study, including number and proportion of patients with prognostic factors, with inclusion and exclusion criteria. Also record numbers of patients who started and completed the study.

[5] Participant characteristics: characteristics relevant to the area of interest: age, sex, ethnic origin, comorbidity, disease status, community- or hospital-based. Include method used to select participants.


[7] Length of follow-up: the length of time that patients take part in the study for, from entry until either a pre-specified end-point (for example, death, specified length of disease-free remission) or the end of the data-gathering phase is reached. If the study is stopped earlier than originally planned for any reason, this should be noted here.

[8] Outcome measures: all outcome measures should be listed, with each on a separate line.

[9] Results: relative risk or hazard associated with the prognostic factor of interest; absolute risk of event in baseline group; time-to-event analysis.
[10] Source of funding: government funding (for example, NHS), voluntary/charity (for example, Wellcome Trust), pharmaceutical company; and the role of funding organisations.

[11] Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (++, +, - if used) or for use in GRADE assessment

[12] Additional comments: additional characteristics and/or interpretations of the studies that the reviewer wishes to record. These might include important flaws in the study not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the study.
### Example of an evidence table for qualitative studies

**Title:** (review question)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Research parameters</th>
<th>Population</th>
<th>Results</th>
<th>Limitations</th>
<th>Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bibliographic reference</td>
<td>Study quality</td>
<td>Research question</td>
<td>Theoretical approach</td>
<td>Data collection</td>
<td>Method and process of analysis</td>
</tr>
</tbody>
</table>

The detailed information under each heading should be agreed at the review protocol stage and be consistently completed across the review. The italicised text above is provided as an example of the types of information that could be included. The required information is specified below.


[2] Research question: what were the research questions?

[3] Theoretical approach: what theoretical approach (for example, grounded theory, interpretive phenomenological analysis) does the study take (if specified)?

[4] Data collection: how were the data collected? Give details of:

- methods
- by whom
- when.

[5] Method and process of analysis: what methods were used to analyse the data (for example, constant comparative method)?

[6] Population and sample collection: what population was the sample recruited from? Include the following information:
- how they were recruited (for example, specify the type of purposive sampling)
- how many participants were recruited
- specific exclusion criteria
- specific inclusion criteria.

[7] Settings: The settings where the qualitative study was undertaken.

[8] Key themes: list all relevant to this review (with illustrative quotes if available).

[9] Source of funding: for example the Department of Health or Economic and Social Research Council, and the role of funding organisations.

[10] Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (++, +, - if used) or for use in GRADE assessment

[11] Limitations: both those identified by the authors and those identified by the reviewer.

[12] Evidence gap and/or recommendations for future research.
### Example of an evidence table for economic evaluation studies

<table>
<thead>
<tr>
<th>Bibliographic reference</th>
<th>Study type</th>
<th>Study quality</th>
<th>Setting</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Number of participants</th>
<th>Participant characteristics</th>
<th>Methods of analysis</th>
<th>Results</th>
<th>Limitations</th>
<th>Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The detailed information under each heading should be agreed at the review protocol stage and be consistently completed across the review.

The italicised text above is provided as an example of the types of information that could be included. The required information is specified below.

Please complete for all headings and note where data is ‘Not reported’ or ‘Not applicable’.

1. **Bibliographic reference**: authors, year, article title, journal, volume, pages.
2. **Study type**: for example, randomised controlled trial with economic evaluation.
3. **Number of participants**: total number of participants included in the study, including number of participants in each arm, with inclusion and exclusion criteria. Also record the numbers of participants who started and completed the study.
4. **Participant characteristics**: characteristics relevant to the area of interest: age, sex, ethnic origin, condition status and comorbidity.
5. **Intervention**: treatment, service, procedure or test studied. If important for the study, specify duration of treatment.
6. **Setting**: the settings where the interventions was delivered (for example care homes).
7. **Comparison**: alternative treatment or ‘standard care’.
8. **Length of follow-up**: the length of time that participants take part in the study for, from first staging treatment until either a pre-specified end-point or the end of the data-gathering phase is reached. If the study is stopped earlier than originally planned for any reason, this should be noted here.
9. **Outcome measures**: list all outcome measures defined in the review protocol, including associated harms.
[10] Effect size: for example, raw data from the study that allow further analyses, as required. Give confidence intervals whenever possible.

[11] Source of funding: for example the Department of Health or Economic and Social Research Council. Also detail the role of funding organisations.

[12] Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (++, +, - if used) or for use in GRADE assessment.

[13] Additional comments: additional characteristics and/or interpretations of the studies that the reviewer wishes to record. These might include important flaws and limitations in the study not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the study.
**GRADE profile and economic evidence profile**

This aims to give examples of profiles that can be used when developing guidelines. The decision about which information to be included in the profile should be made as part of the review protocol development. The profile should include features considered important – these may be study design specific or specific to the topic. As such, additional items may need to be included, or minor modification made. Where this is the case, this should be documented, and where significant, agreed with the NICE QA team.

**Worked example of a GRADE profile**

**Review question:** Should duloxetine vs placebo be used for painful diabetic neuropathy?

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>No. of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. of studies</strong></td>
<td><strong>Design</strong></td>
<td><strong>Risk of bias</strong></td>
<td><strong>Inconsistency</strong></td>
<td><strong>Indirectness</strong></td>
</tr>
<tr>
<td><strong>Patient-reported 30% pain reduction (follow-up 12 weeks)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Randomised trials</td>
<td>No serious risk of bias</td>
<td>Serious</td>
<td>No serious indirectness</td>
</tr>
<tr>
<td><strong>No. of withdrawals due to adverse effects (follow-up 12 weeks)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Randomised trials</td>
<td>No serious risk of bias</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
</tr>
<tr>
<td><strong>Dizziness (adverse effects) (follow-up 12 weeks)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Randomised trials</td>
<td>No serious risk of bias</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
</tr>
<tr>
<td><strong>GI disturbances (adverse effects) (follow-up 12 weeks)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Randomised trials</td>
<td>No serious risk of bias</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
</tr>
<tr>
<td><strong>Any adverse effects (non-specified) (follow-up 12 weeks)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Randomised trials</td>
<td>No serious risk of bias</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
</tr>
</tbody>
</table>

1 Gao et al. (2010); Wernicke et al. (2006).
2 Substantial heterogeneity, random-effect model was used. Potential sources of heterogeneity: i) Gao et al. (2010) – ITT data available, used flexible dose between 30 mg and 120 mg, non-pharmaceutical company funded; ii) Wernicke et al. (2006) – only per-protocol data available, combined 2 fixed doses (60 mg and 120 mg), pharmaceutical company funded.
3 Gao et al. (2010); Goldstein et al. (2005); Raskin et al. (2005); Wernicke et al. (2006).
4 Substantial heterogeneity, random-effect model was used. Potential sources of heterogeneity: i) Gao et al. (2010) – used flexible dose between 30 mg and 120 mg, non-pharmaceutical company funded; ii) Goldstein et al. (2005), Raskin et al. (2005) and Wernicke et al. (2006) – combined different fixed doses (20 mg, 60 mg and 120 mg), pharmaceutical company funded.
Abbreviations: CI, confidence interval; GI, gastrointestinal; ITT, intention to treat; MID, minimal important difference; RR, relative risk.

Example of an uncompleted GRADE profile

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>No. of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of studies</td>
<td>Design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
<td>Indirectness</td>
</tr>
<tr>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[References, abbreviations and other footnotes].
Worked example of an economic evidence profile
Adapted from Crohn’s disease: management in adults, children and young people (NICE clinical guideline 152).

Systematic review of economic evaluations of budesonide for maintenance of remission in Crohn’s disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Limitations</th>
<th>Applicability</th>
<th>Other comments</th>
<th>Incremental Costs</th>
<th>Effects</th>
<th>Cost effectiveness</th>
<th>Uncertainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noble 1998</td>
<td>Potentially serious limitations¹,²</td>
<td>Partially applicable³</td>
<td>Study employed a Markov decision-analytic model with a 1-year time horizon</td>
<td>£115</td>
<td>0.017 QALYs⁵</td>
<td>£6,981 per QALY gained</td>
<td>Incremental cost effectiveness ratio (ICER) decreases significantly if the cost of surgery is increased.</td>
</tr>
<tr>
<td>Budesonide controlled ileal release versus no maintenance therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Clinical Guideline Centre model</td>
<td>Potentially serious limitations²</td>
<td>Directly applicable</td>
<td>Study employed a Markov decision-analytic model with a 2-year time horizon</td>
<td>£477⁶</td>
<td>0.012 QALYs⁶</td>
<td>£40,392 per QALY gained⁶</td>
<td>No treatment most cost-effective option when baseline risk of relapse decreased.</td>
</tr>
<tr>
<td>Oral budesonide versus no maintenance therapy⁴</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>In the probabilistic sensitivity analysis (PSA), probability of budesonide being the most cost-effective treatment at willingness-to-pay threshold of £20,000 per QALY gained ranged from 0 to 8%</td>
</tr>
<tr>
<td>Modelling was undertaken over a short time horizon and no probabilistic sensitivity analysis was conducted.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific costs and disutilities of drug-related adverse events could not be explicitly modelled. Adverse events were captured by modelling treatment-specific withdrawal rates. This may have overestimated the cost effectiveness of maintenance treatment.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The cost-effectiveness model was designed to reflect the management of Crohn’s disease in the Swedish healthcare setting. Although a cost per QALY estimate was reported, it was not based on health-related quality of life values elicited from patients.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The NCGC model compared a number of different maintenance treatments.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Figures may differ because of rounding off.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conservative 4-line model. Conservative treatment effects were used and people relapsing while on azathioprine maintenance treatment had a different induction sequence.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conservative three-line model. Conservative treatment effects were used and people were assumed to have the same 6 induction sequence regardless of maintenance treatment.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ Modelling was undertaken over a short time horizon and no probabilistic sensitivity analysis was conducted.
² Specific costs and disutilities of drug-related adverse events could not be explicitly modelled. Adverse events were captured by modelling treatment-specific withdrawal rates. This may have overestimated the cost effectiveness of maintenance treatment.
³ The cost-effectiveness model was designed to reflect the management of Crohn's disease in the Swedish healthcare setting. Although a cost per QALY estimate was reported, it was not based on health-related quality of life values elicited from patients.
⁴ The NCGC model compared a number of different maintenance treatments.
⁵ Figures may differ because of rounding off.
⁶ Conservative 4-line model. Conservative treatment effects were used and people relapsing while on azathioprine maintenance treatment had a different induction sequence.
⁷ Conservative three-line model. Conservative treatment effects were used and people were assumed to have the same 6 induction sequence regardless of maintenance treatment.
Example of an uncompleted economic evidence profile

<table>
<thead>
<tr>
<th>Study</th>
<th>Limitations</th>
<th>Applicability</th>
<th>Other comments</th>
<th>Incremental</th>
<th>Uncertainty</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Costs</td>
<td>Effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[References, abbreviations and other footnotes].
Notes on use of economic evidence profiles
The economic evidence profile includes columns for the overall assessments of study limitations and applicability as identified using an appropriate checklist. There is also a comments column to note particular issues that the Committee should consider when assessing the economic evidence. Footnotes should be used to explain the reasons for quality assessments.

The results of the economic evaluations can be presented in the form of a best-available estimate or range for the incremental cost, the incremental effect and, where relevant, the incremental cost-effectiveness ratio (ICER) or net benefit estimate. A summary of the extent of uncertainty about the estimates should also be presented in the economic evidence profile. This should reflect the results of deterministic or probabilistic sensitivity analyses or stochastic analyses of trial data, as appropriate.

Each economic evaluation should usually be presented in a separate row of the economic evidence profile. If large numbers of economic evaluations of sufficiently high quality and applicability are available, a single row could be used to summarise a number of studies based on shared characteristics; this should be explicitly justified in a footnote.

Inconsistency between the results of economic evaluations will be shown by differences between rows of the economic evidence profile (a separate column examining ‘consistency’ is therefore unnecessary). The Committee should consider the implications of any unexplained differences between model results when assessing the body of evidence and drawing up recommendations. This includes clearly explaining the Committee’s preference for certain results when forming recommendations.

If results are available for 2 or more subgroups, these should be presented in separate economic evidence profile tables or as separate rows within a single table.

Costs and cost-effectiveness estimates should only be presented for appropriate incremental comparisons; that is, where an intervention is compared with the next most expensive non-dominated option. If comparisons are relevant only for some groups of the population (for example, people who cannot tolerate 1 or more of the
other options, or for whom 1 or more of the options is contraindicated), this should be stated in a footnote to the economic evidence profile.